Hainan Shuangcheng Pharmaceut Net Asset Quality Index
Hainan Shuangcheng Pharmaceut net asset quality index. Hainan Shuangcheng Pharmaceut (002693) has a Net Asset Quality Index of 53.0% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥810.55 Million minus total liabilities of CN¥381.09 Million yields net assets of CN¥429.45 Million. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Hainan Shuangcheng Pharmaceut for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hainan Shuangcheng Pharmaceut (2009–2025)
Net asset quality index of Hainan Shuangcheng Pharmaceut from 2009 to 2025. This chart shows how Hainan Shuangcheng Pharmaceut's Net Asset Quality Index has evolved across 17 annual periods from 2009 to 2025. As of June 2026, the index stands at 53.0%, representing net assets of CN¥429.45 Million against total assets of CN¥810.55 Million CNY. Check strategic asset allocation of Hainan Shuangcheng Pharmaceut to assess the company's strategic physical and investment asset allocation.
Hainan Shuangcheng Pharmaceut Net Asset Quality Index by Year (2009–2025)
Hainan Shuangcheng Pharmaceut net asset quality index by year from 2009 to 2025. The table below presents the year-by-year Net Asset Quality Index for Hainan Shuangcheng Pharmaceut from 2009 to 2025, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 002693 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 50.9% | CN¥420.53 Million | CN¥825.78 Million | CN¥405.25 Million | ▼ -1.6 pp |
| 2024 | 52.5% | CN¥411.61 Million | CN¥783.87 Million | CN¥372.26 Million | ▼ -11.9 pp |
| 2023 | 64.4% | CN¥517.65 Million | CN¥803.25 Million | CN¥285.60 Million | ▲ +0.7 pp |
| 2022 | 63.8% | CN¥580.94 Million | CN¥911.02 Million | CN¥330.08 Million | ▼ -2.6 pp |
| 2021 | 66.3% | CN¥566.75 Million | CN¥854.56 Million | CN¥287.80 Million | ▲ +0.4 pp |
| 2020 | 65.9% | CN¥598.31 Million | CN¥907.68 Million | CN¥309.37 Million | ▼ -5.4 pp |
| 2019 | 71.3% | CN¥678.26 Million | CN¥950.98 Million | CN¥272.72 Million | ▲ +11.5 pp |
| 2018 | 59.8% | CN¥669.69 Million | CN¥1.12 Billion | CN¥450.56 Million | ▲ +4.5 pp |
| 2017 | 55.3% | CN¥761.71 Million | CN¥1.38 Billion | CN¥615.41 Million | ▲ +7.9 pp |
| 2016 | 47.5% | CN¥553.13 Million | CN¥1.17 Billion | CN¥612.40 Million | ▼ -12.4 pp |
| 2015 | 59.8% | CN¥927.61 Million | CN¥1.55 Billion | CN¥622.56 Million | ▼ -34.9 pp |
| 2014 | 94.7% | CN¥893.55 Million | CN¥943.54 Million | CN¥49.99 Million | ▼ -0.2 pp |
| 2013 | 94.9% | CN¥870.62 Million | CN¥917.04 Million | CN¥46.42 Million | ▼ -0.5 pp |
| 2012 | 95.4% | CN¥845.85 Million | CN¥886.65 Million | CN¥40.80 Million | ▲ +3.4 pp |
| 2011 | 92.0% | CN¥228.23 Million | CN¥248.06 Million | CN¥19.83 Million | ▲ +29.6 pp |
| 2010 | 62.4% | CN¥157.82 Million | CN¥252.73 Million | CN¥94.92 Million | ▼ -17.2 pp |
| 2009 | 79.7% | CN¥77.95 Million | CN¥97.85 Million | CN¥19.91 Million | — |